ERRATUM: AACR: Paclitaxel Carboplatin Combination Therapy Might Be as Effective as Mitoxantrone Alone for Patients With Hormone-Refractory Prostate Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




ERRATUM: AACR: Paclitaxel Carboplatin Combination Therapy Might Be as Effective as Mitoxantrone Alone for Patients With Hormone-Refractory Prostate Cancer

There was an error in a recent article from our coverage of the American Association for Cancer Research 95th Annual Meeting.

The original text read:
ORLANDO, FL -- April 1, 2004 -- Preliminary results of a phase 2 study suggest that a paclitaxel/carboplatin combination may be as effective as taxotere alone for patients with hormone refractory prostate cancer, researchers reported in a poster session here at the American Association for Cancer Research 95th Annual Meeting.

"The major finding of our study is that hormone resistant prostate cancer must not be considered any more as chemoresistant," said presenter Philippe Chollet, MD, Centre Jean Perrin, Clermont-Ferrand, France. "Taxol carboplatin is a good and effective combination as taxotere alone is. In addition, prostate cancer must be treated in the same way as breast cancer."

The corrected text now reads:
ORLANDO, FL -- April 1, 2004 -- Preliminary results of a phase 2 study suggest that a paclitaxel plus carboplatin combination may be as effective as mitoxantrone alone for patients with hormone refractory prostate cancer, researchers reported in a poster session here at the American Association for Cancer Research 95th Annual Meeting.

"The major finding of our study is that hormone resistant prostate cancer must not be considered any more as chemoresistant," said presenter Philippe Chollet, MD, Centre Jean Perrin, Clermont-Ferrand, France. "Taxol carboplatin is a good and effective combination as mitoxantrone alone is. In addition, prostate cancer must be treated in the same way as breast cancer."

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities